Results 241 to 250 of about 63,337 (330)
Main Points Multiple sclerosis involves chronic CNS inflammation and neurodegeneration. This review highlights glial cells as key drivers in progressive MS, focusing on lesion pathology, molecular dysfunction, and human‐relevant model systems. ABSTRACT Multiple sclerosis (MS) is the most common non‐infectious inflammatory CNS disease, characterized by ...
Volker Siffrin
wiley +1 more source
Primary and secondary metastatic dissemination: multiple routes to cancer-related death. [PDF]
Sparrer D+21 more
europepmc +1 more source
What's new? About half of penile squamous cell carcinomas are causally associated with inflammatory conditions such as lichen sclerosus (LSc), but few large‐scale studies have assessed the risk of penile cancer in men with LSc. Here, the authors conducted a large nationwide study in Denmark to estimate the risk of penile and non‐penile cancer in men ...
Marianne Gardar Stærk+5 more
wiley +1 more source
Main Points Absence of DBN leads to larger spinal lesions, immune cell infiltration and attenuated astrocyte reactivity in the early phase post SCI. Absence of DBN leads to greater neurodegeneration, underscoring its importance in tissue repair.
Barbora Smejkalová+12 more
wiley +1 more source
Rhombencephalitis, a forgotten diagnosis in the post-partum period: a case report. [PDF]
Islamagič L+5 more
europepmc +1 more source
Primary Progressive Multiple Sclerosis: New Therapeutic Approaches
Primary progressive MS affects 10%–15% of MS patients, causing irreversible neurological impairment. Drugs like ocrelizumab show promise, while high‐dose biotin, simvastatin, and coenzyme Q10 are under investigation. Gene therapy and stem cell treatments also show potential.
Morteza Rajabi+8 more
wiley +1 more source
Lipomatous Dural Metaplasia Associated With Chronic Ventricular Shunting: A Report of Two Cases. [PDF]
Suthar PP+4 more
europepmc +1 more source
The meninges: new therapeutic targets for multiple sclerosis.
Abigail E. Russi, Melissa A Brown
semanticscholar +1 more source